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Summary
Objective: Safety and reactogenicity of a new heptavalent DTPw—HBV/Hib—MenAC (diphtheria,
tetanus, whole cell pertussis—hepatitis B virus/Haemophilus influenzae type b—Neisseria menin-
gitidis serogroups A and C) vaccine was compared with a widely used pentavalent DTPw—HBV/Hib
vaccine.
Methods: Three phase III randomized studies comparable in design and methodology, in which
healthy infants received DTPw—HBV/Hib—MenAC (N = 1334) or DTPw—HBV/Hib (N = 446) at 2, 4,
and 6 months, were pooled for analysis. Solicited symptoms were recorded for 4 days, and
unsolicited adverse events for 31 days after each dose. Serious adverse events (SAEs) were
recorded throughout the studies.
Results: Therewereno significantdifferencesbetween the twogroups in theproportionof subjects
with fever >39.5 8C or >40.0 8C (p < 0.005). Compared to group DTPw—HBV/Hib, a significantly
higher percentage of subjects in group DTPw—HBV/Hib—MenAC reported fever >39 8C (21.2% vs.
14.8%, p = 0.004). Fever subsided quickly, did not lead to differences in attendance to medical
services and did not increase from dose to dose. Sixty-seven SAEs were reported, 56/1334 (4.2%) in
group DTPw—HBV/Hib—MenAC and 11/446 (2.5%) in the DTPw—HBV/Hib group.§ This study was presented as a poster at the 12th International Congress on Infectious Diseases, Lisbon, Portugal, June 15—18, 2006.
* Corresponding author. Tel.: +32 2 656 9136; fax: +32 2 656 8044.
E-mail address: kurt.dobbelaere@gskbio.com (K. Dobbelaere).
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Conclusion: Overall, the heptavalent and pentavalent vaccines had similar safety profiles. The
difference observed in percentage of subjects with fever >39 8C did not lead to differences in
medically attended visits for fever.
# 2007 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.Introduction
Effective prevention of disease and deaths in infants caused
by Haemophilus influenzae type b (Hib), Neisseria meningi-
tidis, and Streptococcus pneumoniae only became possible
since the availability of techniques allowing protein conjuga-
tion of bacterial polysaccharides in the manufacturing of
vaccines. The efficacy of Hib and S. pneumoniae conjugate
vaccines in preventing disease in infants has been demon-
strated.1,2 The effectiveness of N. meningitidis serogroup C
(MenC) conjugate vaccines was established in the UK where
widespread vaccination in response to a national epidemic of
MenC disease resulted in marked reductions in disease inci-
dence.3,4
In the past, two combinedmeningococcal A and C (MenAC)
conjugate vaccines using a diphtheria toxoid or mutant
diphtheria toxoid (CRM197) as carrier protein were not
developed commercially despite showing immunogenicity
in infants during clinical studies in Africa.5,6 Subsequently,
the MenA component of one of them failed to demonstrate
induction of immune memory.7
Globally it is estimated that 500 000 cases of meningo-
coccal septicemia and 50 000 deaths due to meningococcal
disease occur each year.8 Case fatality rates may reach 20% in
some regions.8 Infants and children less than 5 years of age
are primarily affected.9
Within Asia and the ‘meningitis belt’ of Africa where
explosive epidemics still occur, the majority of epidemic
meningococcal disease is caused by serogroup A.9—13 Out-
breaks due to MenC14 and more recently W-135 have also
been reported in these regions.15
Adding new vaccines into routine vaccination schedules is
complicated when this entails administration of multiple
injections at a single vaccination visit. When multiple injec-
tions are required there is a higher risk that some vaccine
doses will be deferred and that overall vaccine coverage will
drop as a consequence. In contrast, adding new antigens onto
existing vaccines with high coverage promotes rapid uptake
and high coverage of the new components, while minimizing
cost and logistics of vaccine delivery.
The combined diphtheria—tetanus—whole-cell pertussis—
hepatitis B—Hib vaccine (DTPw—HBV/Hib, TritanrixTM-HepB/
HiberixTM, GlaxoSmithKline Biologicals, Rixensart, Belgium)
is licensed for primary and booster vaccination of infants. The
DTPw—HBV/Hib vaccine contains five antigens currently
recommended by the World Health Organization (WHO)
Expanded Programme on Immunization (EPI).16 Addition of
MenA and MenC conjugate vaccines to DTPw—HBV/Hib would
protect infants against three of the commonest causes of
septicemia and meningitis in young children, in a single
injection. A combined DTPw—HBV/Hib—MenAC vaccine was
shown to be immunogenic and to induce immune memory in
infants primed in an accelerated 6, 10, and 14 week sche-
dule.17 There was no difference in the reactogenicity orsafety profile of the vaccine when compared to subjects
who received licensed DTPw—HBV and Hib vaccines or when
compared to subjects who received the DTPw—HBV/Hib
vaccine co-administered with a licensed MenC conjugate
vaccine.
In order to more fully describe the reactogenicity and
safety profile of the new DTPw—HBV/Hib—MenAC vaccine,
three large randomized, multicenter, partially blinded con-
trolled clinical trials were conducted in which DTPw—HBV/
Hib—MenAC was compared with a widely used DTPw—HBV/
Hib vaccine. Subjects were vaccinated at 2, 4, and 6 months
of age and had received a dose of hepatitis B vaccine at birth.
Presented here is the pooled analysis of safety across the
three studies.
Methods
Study design and subjects
Each of the three studies (study numbers 100480, 100791,
and 759346/004) was designed with the objective of pooling
the individual study data for a global analysis of safety and
reactogenicity. The primary objective was to evaluate the
new DTPw—HBV/Hib—MenAC vaccine compared to the
licensed DTPw—HBV/Hib control group in terms of the per-
centage of subjects with fever >39.0 8C (rectal route). Stu-
dies 100480 and 100791 were conducted in Thailand and
study 759346/004 in the Philippines.
All studies were randomized and controlled. All were
conducted with similar design and reporting methodology.
In all three studies, subjects were randomized (3:1) to
receive one of three lots of the candidate DTPw—HBV/
Hib—MenAC vaccine (group DTPw—HBV/Hib—MenAC) or the
DTPw—HBV/Hib control vaccine (group DTPw—HBV/Hib).
Due to differences in the method of reconstitution of the
two vaccines, the design was open-labeled although the
three vaccine lots were given in a blinded manner. Study
100480 had an additional control group that received DTPw—
HBV/Hib + licensed conjugate MenC vaccine. This group was
not taken into account in the pooled safety analysis.
Healthy infants vaccinated at birth against hepatitis B and
aged between 56 and 83 days at the time of the first vaccina-
tion were eligible for inclusion. In study 759346/004 only,
subjects were enrolled at birth after a gestation period of
36—42 weeks in order to receive hepatitis B vaccine, which is
not part of routine immunization procedures in the Philip-
pines as it is in Thailand.
Subjects were not eligible for participation if they had:
acute disease at the time of enrolment; major congenital
defects/serious chronic illness; neurological disorders/sei-
zures; immunodeficient conditions or a family history of
hereditary immunodeficiency; previous disease or exposure
to vaccine antigens; allergic disease to vaccine components;
use or planned use of investigational drugs/vaccines since
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/blood products before or during the trial; received Bacille
Calmette—Gue´rin vaccine after the first two weeks of life or
administration of other vaccines with the exception of oral
polio vaccine.
The study protocols and associated study documents were
reviewed and approved by relevant ethics committees. The
studies were conducted according to Good Clinical Practice
(GCP) guidelines and the Declaration of Helsinki. Written
informed consent was obtained from the parent/guardian of
every child prior to enrolment in the study.
An independent data monitoring committee (IDMC) was
appointed to oversee ethical and safety aspects of the study
conduct, including review of the implementation and pro-
gress of the study.
Vaccines
All vaccines were developed and manufactured by GlaxoS-
mithKline Biologicals (Rixensart, Belgium). DTPw—HBV
vaccine (TritanrixTM-HepB) contained 30 IU of diphtheria
toxoid,60 IU of tetanus toxoid,4 IU inactivated Bordetella
pertussis, 10 mg recombinant hepatitis B surface antigen
(HBsAg) with 2-phenoxyethanol and thiomersal as preserva-
tive. DTPw—HBVwas used to reconstitute the lyophilizedHib—
MenAC or HiberixTM vaccines. The Hib—MenAC component of
the DTPw—HBV/Hib—MenAC vaccine contained 2.5 mg each of
polyribosylribitol phosphate (PRP), MenA capsular polysac-
charide (PSA), and MenC capsular polysaccharide (PSC), each
conjugated to tetanus toxoid (TT). HiberixTM contained 10 mg
PRP, also conjugated to TT. Three doses of each vaccine were
administered in the left anterolateral part of the thigh at 2, 4,
and 6 months of age.
Assessment of safety
Local and general symptoms were solicited on the day of
vaccination and subsequent three days (4-day follow-up).Figure 1 Number of enrolled subjects and rParents/guardians were asked to record on diary cards any
pain, redness and swelling at injection site, fever (defined as
rectal body temperature 38.0 8C), irritability/fussiness,
drowsiness, and loss of appetite. For each solicited symptom,
the subjects’ parents/guardians were asked if this symptom
resulted in a medically attended visit, defined as a hospita-
lization, an emergency room visit or a visit to or frommedical
personnel (medical doctor) for any reason. The relationship
of solicited general symptoms to the vaccine was determined
by the investigator. All adverse events (unsolicited symp-
toms) occurring within 31 days (day 0—30) after each vaccine
dose were also recorded. Serious adverse events (SAEs) were
recorded during the entire study period.
Statistical methods
The incidence of any symptom, local and general (solicited
and unsolicited), reported during the 4-day follow-up period
was computed, as well as those graded 3 and those for which
medical advice was sought.
The incidence and intensity of each solicited adverse
event, as well as its causal relationship to vaccination was
tabulated. Exact 95% confidence intervals (95% CIs) were
computed using StatXact 5.0 assuming independence
between doses.
The incidence of each symptom occurring after each dose,
after any dose, and on a per subject basis was calculated.
For the per subject analysis, groups were compared using
two-sided p-values from the Fisher’s exact test and the
standardized asymptotic 95% CIs for the differences between
groups. Values of p less than 0.05 were used as an indicator
that a difference between groups might exist.
The primary objective of the study was to evaluate the
incidence of rectal fever>39 8C in both groups. A sample size
of 1350 subjects in the Hib—MenAC group and 450 in the
control group would rule out a 5% increase in fever >39.0 8C
with 95% power assuming an incidence rate of 6% in both
groups.easons for elimination from study cohorts.
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Table 1 Demographic characteristics of the pooled total vaccinated cohort at the time of the first dose of study vaccine
Group Total Female Age (weeks)
N n (%) Mean SD Min Max
DTPw—HBV/Hib—MenAC 1334 661 (49.6%) 9.0 1.00 7 11
DTPw—HBV/Hib 446 214 (48.0%) 9.0 0.98 8 11
N: number in the total vaccinated cohort; n (%): number (percent) of female subjects; SD: standard deviation; min/max: minimum/
maximum age.Results
The three studies were conducted between 11 December
2003 and 30 April 2005. The evaluation of the lot-to-lot
consistency in study 100480 showed that there were no
significant differences across the three Hib—MenAC lots in
terms of solicited symptoms (any, grade 3,>39 8C and>40 8C
for fever; any solicited or unsolicited symptoms resulting in a
medically attended visit) except in terms of the percentage
of subjects for whom loss of appetite was reported, although
there was no difference in vaccination-related loss of appe-
tite. This justifies pooling reactogenicity and safety results
from the three different Hib—MenAC lots that were used in
the three clinical studies. The analysis of safety was
performed on the total vaccinated cohort of 1780 subjects
(1334 in the DTPw—HBV/Hib—MenAC group and 446 in the
DTPw—HBV/Hib group) (Figure 1), representing 3967 admi-
nistered doses of DTPw—HBV/Hib—MenAC and 1330 doses of
DTPw—HBV/Hib vaccine.
Demographic characteristics
All subjects were of Asian origin with 1300 infants vaccinated
in Thailand and 480 in the Philippines. Overall 49.2% of
subjects were female, and subjects were between 7 and
11 weeks of age at the time of the first dose of study vaccine
(Table 1).Table 2 Difference between the groups in the percentage of
vaccination (pooled total vaccinated cohort)
Temperature
(rectal)
DTPw—HBV/Hib—MenAC
(N = 1326)
DTP
(N =
% (95% CI) a % (9
38.0 8C 85.5 (83.5, 87.4) 79.3
38.0 8C related 76.7 (74.3, 78.9) 71.9
>39.5 8C related 3.7 (2.7, 4.9) 2.7
>40.0 8C 1.6 (1.0, 2.4) 0.7
>40.0 8C related 1.3 (0.7, 2.0) 0.7
Medical advice 0.6 (0.3, 1.2) 0.7
>38.5 8C 48.9 (46.2, 51.7) 36.4
>39.0 8C 21.2 (19.0, 23.5) 14.8
>39.5 8C 4.2 (3.2, 5.4) 2.7
Related: fever considered by the investigator to be related to the stu
N: number of subjects with at least one documented dose; %: percenta
medical advice: solicited local/general symptom reported for the
hospitalization, an emergency room visit, or a visit to or from a medic
a CI: exact 95% confidence interval; 95%.
b CI: standardized asymptotic 95% confidence interval.
* Primary objective of the study.Safety
No drop-outs were due to adverse events or serious adverse
events.
Incidence of fever
Themajority of fever episodes that occurred during the 4-day
follow-up after each vaccination were considered by the
investigators to be related to vaccination (Table 2). A total
of 85.5% of DTPw—HBV/Hib—MenAC recipients and 79.3% of
DTPw—HBV/Hib recipients reported fever episodes during
the primary vaccination course ( p = 0.003, Table 2). Impor-
tantly, the proportion of febrile episodes for which medical
attention was sought was small (0.7% of subjects) and was
not significantly different between groups ( p = 1.000). There
was no increase in the incidence of fever with consecutive
vaccine doses (Figure 2).
Significantly more febrile episodes with rectal tempera-
ture >39.0 8C occurred in the DTPw—HBV/Hib—MenAC group
(primary endpoint, p = 0.004). The upper limit of the 95% CI
of the percentage of subjects with fever >39.0 8C (23.5%)
was lower than twice the observed incidence in the control
group (2  14.8% = 29.6%); a doubling of fever incidence has
been excluded by this study.
Because of the observation of this significant difference in
febrile episodes with rectal temperature >39.0 8C betweensubjects with fever during the 4-day follow-up period after
w—HBV/Hib
445)
Difference (DTPw—HBV/
Hib—MenAC — DTPw—HBV/Hib)
5% CI) % (95% CI)b p-Value
(75.3, 83.0) 6.19 (2.16, 10.59) 0.003
(67.5, 76.0) 4.79 (0.16, 9.66) 0.048
(1.4, 4.7) 1.00 (1.13, 2.65) 0.369
(0.1, 2.0) 0.91 (0.46, 1.88) 0.234
(0.1, 2.0) 0.61 (0.75, 1.52) 0.437
(0.1, 2.0) 0.07 (1.39, 0.67) 1.000
(31.9, 41.1) 12.54 (7.25, 17.66) 0.000
(11.7, 18.5) 6.36 (2.20, 10.16) 0.004 *
(1.4, 4.7) 1.53 (0.63, 3.23) 0.157
dy vaccine; p-value: two-sided Fisher’s exact test; 95%.
ge of subjects who reported at least once the specified symptom;
subject that required medical attention that was defined as a
al personnel (medical doctor).
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Figure 2 Percentage of subjects (with 95% CIs) with solicited symptoms after each vaccine dose. Grade 3 symptoms: pain — cried
when limb was moved/spontaneously painful; redness and swelling >30 mm; drowsiness that prevented normal activity; irritability/
fussiness — crying that could not be comforted/prevented normal activity; loss of appetite — not eating at all; rectal fever >40.0 8C.groups, fever data were analyzed per individual study and are
shown in Table 3. The difference between groups appears
higher in the Philippines than in Thailand.
There was no difference between groups in the proportion
of subjects who took prophylactic antipyretic medication
before the administration of each vaccine (15.4% and
15.9% in groups DTPw—HBV/Hib—MenAC and the control
group, respectively, p = 0.821). Significantly more subjects
in the DTPw—HBV/Hib—MenAC group took an antipyretic
agent during the 4-days following each vaccination (67.3%
vs. 58.3% in the control group, p < 0.001).Other solicited symptoms
Pain was the most commonly reported solicited local
symptom that occurred after vaccination in both groups
(Table 4). Local symptoms of grade 3 intensity were uncom-
mon, occurring after 8.9% of doses or fewer. Only one subject
underwent a medically attended visit for swelling at the
injection site.
Irritability was the most commonly reported systemic
solicited symptom (Table 5). Drowsiness, irritability, and loss
of appetite of grade 3 intensity were uncommonly reported,
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.occurring after 0.8% to 3.7% of DTPw—HBV/Hib—MenAC doses
and 0.3% to 2.8% of DTPw—HBV/Hib doses.
Exploratory comparisons of the per subject analysis
showed significant differences in the incidence of injection
site pain, swelling, and in loss of appetite between groups,
with a higher frequency of events in the DTPw—HBV/Hib—
MenAC group than the control group ( p < 0.05 for all). There
were no significant differences between groups in terms of
the incidence of symptoms of grade 3 intensity (or>40 8C for
fever) or in the proportion of events that resulted in a
medically attended visit.
Other symptoms
Two percent of DTPw—HBV/Hib—MenAC doses and 2.6% of
DTPw—HBV/Hib doses were followed by the report of an
unsolicited symptom considered by the investigators to be
related to vaccination. The most commonly reported related
symptoms were: injection site induration (following 0.8% and
1.0% of doses in the DTPw—HBV/Hib—MenAC and DTPw—
HBV/Hib groups, respectively), rash (0.3% and 0.3%), vomit-
ing (0.3% and 0.5%), and diarrhea (0.2% and 0.4%). Other
symptoms were also of similar pattern in each of the two
groups.
Serious adverse events
Sixty-seven infants had SAEs reported during the studies, 56
of the 1334 subjects vaccinated with DTPw—HBV/Hib—
MenAC vaccine (4.2%) and 11 of the 446 subjects who
received control vaccine (2.5%). All SAEs resolved without
sequelae with the exception of two cases of congenital
cataract that were diagnosed 7 weeks after the first dose
of DTPw—HBV/Hib—MenAC vaccine in twins and a case of
thalassemia that was diagnosed after the birth dose of
hepatitis B vaccine (i.e., prior to DTPw vaccination).
Of them, a total of six SAEs were considered by the
investigators to have a causal relationship to vaccination:
five cases of convulsion, all in Thai infants, occurred within
24 hours after vaccination with DTPw—HBV/Hib—MenAC;
four of these were reported after dose 1 and the fifth was
after dose 3. In all cases, fever was present on the day of
convulsion. The convulsions were of short duration and
resolved on the same day without sequelae. All subjects
who had a febrile convulsion after dose 1 received subse-
quent doses of study vaccine without incident.
The sixth case considered to be related to vaccination was
an infant who was hospitalized with a maculopapular rash and
low-grade fever that developed in the two days following the
first dose of DTPw—HBV/Hib—MenAC. A possible allergic reac-
tion to the vaccine was diagnosed. The subject recovered and
received subsequent vaccine doses without incident.
Discussion
Routine vaccination against MenA and MenC is the only way to
provide durable, widespread protection of infants and chil-
dren against potentially disabling or fatal meningococcal
disease. The novel combined DTPw—HBV/Hib—MenAC vac-
cine provides an exciting opportunity for disease prevention
in regions where MenA and MenC are endemic, and where
epidemics occur, causing an average annual incidence rate of
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Table 4 Percentage of subjects/doses followed by solicited local symptoms during the 4-day follow-up period after vaccination
(pooled total vaccinated cohort)
Symptoms Type DTPw—HBV/Hib—MenAC DTPw—HBV/Hib
% (95% CI) % (95% CI)
Percentage of subjects N = 1326 N = 445
Pain All 87.1* (85.2, 88.9) 81.6* (77.7, 85.1)
Grade 3 20.2 (18.1, 22.5) 17.3 (13.9, 21.1)
Medical advice 0.0 (0.0, 0.3) 0.0 (0.0, 0.8)
Redness All 70.7 (68.2, 73.2) 70.1 (65.6, 74.3)
>30 mm 5.1 (3.9, 6.4) 4.9 (3.1, 7.4)
Medical advice 0.0 (0.0, 0.3) 0.0 (0.0, 0.8)
Swelling All 56.8* (54.1, 59.5) 51.2* (46.5, 56.0)
>30 mm 10.5 (8.9, 12.3) 11.2 (8.5, 14.5)
Medical advice 0.1 (0.0, 0.4) 0.0 (0.0, 0.8)
Percentage of doses N = 3958 N = 1326
Pain All 66.4 (64.9, 67.9) 58.0 (55.3, 60.7)
Grade 3 8.9 (8.0, 9.8) 6.8 (5.5, 8.3)
Medical advice 0.0 (0.0, 0.1) 0.0 (0.0, 0.3)
Redness All 47.2 (45.7, 48.8) 44.8 (42.1, 47.5)
>30 mm 2.1 (1.7, 2.6) 2.0 (1.3, 2.9)
Medical advice 0.0 (0.0, 0.1) 0.0 (0.0, 0.3)
Swelling All 36.4 (34.9, 38.0) 31.5 (29.0, 34.1)
>30 mm 4.9 (4.2, 5.6) 4.6 (3.5, 5.9)
Medical advice 0.0 (0.0, 0.1) 0.0 (0.0, 0.3)
N: number of subjects reporting at least once the symptom/number of documented doses; %: percentage of subjects reporting at least once
the symptom/percentage of doses followed by at least one type of symptom; 95% CI: exact 95% confidence interval; grade 3 pain: cried when
limb was moved/spontaneously painful; medical advice: solicited local symptom reported for the subject for which medical attention was
sought (medical attention was defined as a hospitalization, an emergency room visit or a visit to or from a medical personnel (medical
doctor)).
* p < 0.05 by two-sided Fisher’s exact test, per subject analysis only.meningitis as high as 37.4% in infants below one year of age,
and a case—fatality ratio of 19.3%.9 It provides MenA and
MenC conjugate vaccines in a single injection17 with cur-
rently recommended EPI antigens.
The primary objective of this study was to evaluate the
study vaccine in terms of the incidence of rectal fever
>39.0 8C. A significant difference between groups was
observed. There were no significant differences between
the two groups in the proportion of subjects with fever
>39.5 8C or >40.0 8C nor in the proportion of subjects with
fever who visited a medical practitioner for assessment and
treatment of the febrile episode.
Following vaccination with DTPw—HBV/Hib—MenAC or
DTPw—HBV/Hib, local and systemic reactions were common
in both groups. The point estimates for the incidence of local
and systemic symptoms occurring after vaccination were
generally higher in the DTPw—HBV/Hib—MenAC group than
in the control group, reaching statistical significance for
pain, swelling, loss of appetite, and fever (>38.0 8C and
>39.0 8C), although there was no difference between groups
in the incidence of symptoms of grade 3 intensity or in fever
>40.0 8C.
The somewhat higher incidence of reactogenicity noted in
the DTPw—HBV/Hib—MenAC group compared to the control
group is likely to be due to the additional two antigensreceived by the DTPw—HBV/Hib—MenAC group. There was
no difference between groups in the nature or severity of
unsolicited symptoms that were reported after vaccination.
The nature of adverse reaction following vaccination with the
DTPw—HBV/Hib—MenAC vaccine resembled the safety profile
of the DTPw—HBV/Hib vaccine used as the control, and
resembles the safety profile of other whole-cell based per-
tussis vaccines.18—22
Fever is a common reaction to vaccination in children and
is known to be associated with whole-cell pertussis-contain-
ing vaccines. Fever occurs after one out of every two doses of
DTPw vaccine administered,18,19 although in the vast major-
ity of cases, the fever is benign and short-lived. Fever itself is
considered to be an adaptive response and is associated with
heightened T-cell activity, enhanced antigen recognition,
and specific immune responses to antigen.23 Elevated body
temperature rarely presents a risk to children who are
otherwise healthy.24
Febrile convulsions are a relatively common event in
childhood and occur in 3—4% of children before the age of
7 years, although the incidence varies between coun-
tries.23,25 In our study, convulsions that were considered to
be related to vaccination were all reported in Thailand. The
incidence of febrile convulsion was not statistically different
from the incidence in the Philippines ( p = 0.332). However, it
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Table 5 Percentage of subjects/doses followed by solicited general symptoms during the 4-day follow-up period after vaccination
(pooled total vaccinated cohort)
Symptoms Type DTPw—HBV/Hib—MenAC DTPw—HBV/Hib
% (95% CI) % (95% CI)
Percentage of subjects N = 1326 N = 445
Drowsiness All 77.1 (74.8, 79.4) 75.3 (71.0, 79.2)
Grade 3 3.2 (2.4, 4.3) 3.1 (1.7, 5.2)
Medical advice 0.2 (0.0, 0.7) 0.2 (0.0, 1.2)
Irritability All 88.8 (86.9, 90.4) 85.6 (82.0, 88.7)
Grade 3 9.7 (8.1, 11.4) 7.2 (5.0, 10.0)
Medical advice 0.2 (0.0, 0.7) 0.4 (0.1, 1.6)
Loss of appetite All 54.2* (51.5, 56.9) 48.8* (44.0, 53.5)
Grade 3 2.0 (1.3, 2.9) 0.9 (0.2, 2.3)
Medical advice 0.2 (0.0, 0.5) 0.0 (0.0, 0.8)
Percentage of doses N = 3958 N = 1326
Drowsiness All 54.6 (53.0, 56.2) 49.2 (46.4, 51.9)
Grade 3 1.3 (0.9, 1.7) 1.1 (0.6, 1.8)
Medical advice 0.1 (0.0, 0.2) 0.1 (0.0, 0.4)
Irritability All 69.0 (67.5, 70.4) 63.6 (60.9, 66.2)
Grade 3 3.7 (3.1, 4.4) 2.8 (2.0, 3.8)
Medical advice 0.1 (0.0, 0.2) 0.2 (0.0, 0.5)
Loss of appetite All 29.7 (28.3, 31.2) 26.1 (23.7, 28.5)
Grade 3 0.8 (0.5, 1.1) 0.3 (0.1, 0.8)
Medical advice 0.1 (0.0, 0.2) 0.0 (0.0, 0.3)
Fever 38.0 8C 58.6 (57.0, 60.1) 51.4 (48.6, 54.1)
>40.0 8C 0.6 (0.3, 0.8) 0.2 (0.0, 0.7)
Medical advice 0.2 (0.1, 0.4) 0.2 (0.0, 0.7)
95% CI: exact 95% confidence interval; N: number of subjects reporting at least once the symptom/number of documented doses; %:
percentage of subjects reporting at least once the symptom/percentage of doses followed by at least one type of symptom; medical advice:
solicited local/general symptom reported for the subject for which medical attention was sought (medical attention was defined as a
hospitalization, an emergency room visit or a visit to or from a medical personnel (medical doctor)); grade 3 drowsiness: drowsiness that
prevented normal activity; grade 3 irritability/fussiness: crying that could not be comforted/prevented normal activity; grade 3 loss of
appetite: not eating at all.
* p < 0.05 by two-sided Fisher’s exact test, per subject analysis only.has to be noted that three quarters of the subjects were
enrolled and vaccinated at the Thai centers, making it more
likely to observe febrile convulsions in the two Thai studies
than in the study in the Philippines. An analysis of fever per
country and individual study did not show a higher incidence
of fever in the subjects in the Thai studies. On the contrary,
fever after DTPw—HBV/Hib—MenAC, as well as difference
between groups appear higher in the Philippines than in
Thailand, hence difference in fever post-vaccination in the
two countries could not explain the occurrence of convul-
sions in Thai infants only. Febrile convulsions may result from
fever induced by any cause, including vaccination. An
increased risk of febrile convulsion on the day of vaccination
has been associated with receipt of whole-cell pertussis
vaccines (relative risk 5.70, 95% CI 1.98, 16.4226). In a key
study describing adverse reactions following DTPw vaccina-
tion by Cody et al., one case of febrile convulsion occurred
for every 1750 doses administered (0.057% (95% CI: 0.026—
0.108)).18 In a clinical study with GlaxoSmithKline Biologi-
cals’ DTPw—HBV/Hib2.5 vaccine (QuintanrixTM), two febrileconvulsions occurred with temporal relationship to primary
vaccination after almost 2000 doses.27 In the current study,
there were five febrile convulsions considered to be related
to DTPw—HBV/Hib—MenAC vaccine after 3967 doses (0.126%
(95% CI: 0.041—0.294)); in the control group, there were
none after 1330 doses (0% (95% CI: 0—0.277)). In clinical
studies with GlaxoSmithKline Biologicals’ Hib—MenC (Meni-
torixTM) and Hib—MenCY conjugate vaccines that are co-
administered with acellular pertussis-containing vaccines,
no febrile convulsions were reported following vaccination.
Though the data of the current study do not allow the
exclusion of a difference in incidence of related febrile
convulsions between groups, especially in a Thai population,
reassuring evidence is available in the literature18,27 and
from clinical experiences with meningococcal conjugate
vaccines co-administered with DTPa-containing vaccines
to conclude that the febrile convulsions are most likely
due to the whole cell pertussis component of the vaccines.
Additionally, subjects who had a febrile convulsion after dose
1 of DTPw—HBV/Hib—MenAC vaccine received subsequent
96 A. Kerdpanich et al.vaccinations with the same vaccine without incident. This is
in keeping with the benign nature of febrile seizures whereby
subjects who experience febrile convulsion after vaccination
are not at higher risk for subsequent neurological events.26
In 1334 subjects who received vaccination with the novel
combined DTPw—HBV/Hib—MenAC vaccine, reactions and
adverse events that followed vaccination were those typi-
cally associated with vaccination with whole-cell pertussis
vaccines. Febrile convulsion occurred at previously reported
rates. Furthermore, the incidence of fever was in the same
range as that reported in previous studies of whole-cell
pertussis vaccine combinations. No specific safety issues
were raised during this study.
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